Report Library
All Reports
2015 ASCO Mid-Weekend Pulse Survey
*Included free with BioMedTracker Subscription - click here to log inMay 31, 2015
We performed a 5-question survey of 40 US oncologists during ASCO meeting weekend to
gauge interest in
new data presented on experimental drugs.
Drug candidates and indications discussed: Alectinib (Roche) for NSCLC, Nivolumab (BMY) for NSCLC, Pembrolizumab (MRK) for NSCLC, and Rindopepimut (CLDX) for Glioblastoma.
To download the ASCO Pulse Survey, click the link at the top of the page.
For our disclosures, please read the BioMedTracker Research Standards. BioMedTracker will be offering KOL Reports and Physician Pulse Surveys through 2015 for purchase a la carte, or access to all reports and surveys can be purchased as a subscription to KOL Insight. For more information on KOL Insight subscription, please email BioMedTracker or call BioMedTracker Client Services at (858) 200-2357.
Drug candidates and indications discussed: Alectinib (Roche) for NSCLC, Nivolumab (BMY) for NSCLC, Pembrolizumab (MRK) for NSCLC, and Rindopepimut (CLDX) for Glioblastoma.
To download the ASCO Pulse Survey, click the link at the top of the page.
For our disclosures, please read the BioMedTracker Research Standards. BioMedTracker will be offering KOL Reports and Physician Pulse Surveys through 2015 for purchase a la carte, or access to all reports and surveys can be purchased as a subscription to KOL Insight. For more information on KOL Insight subscription, please email BioMedTracker or call BioMedTracker Client Services at (858) 200-2357.
| Indications Covered: |
Brain Cancer (Malignant Glioma; AA and glioblastoma (GBM))
Brain Cancer (Secondary; Metastases) Non-Small Cell Lung Cancer (NSCLC) |
Additional Resources: